Nicotine Withdrawal and Junk Food Intake: A Study

Mar.28.2022
Nicotine Withdrawal and Junk Food Intake: A Study
Nicotine withdrawal symptoms vary and peak after 1-3 days, but psychological effects can persist. Quitting smoking often leads to increased junk food cravings.

According to a report by foreign media on March 27, 2022, it is well known that the symptoms of nicotine withdrawal vary from person to person, with some struggling more than others. However, these symptoms generally peak in the first 1-3 days of quitting smoking and gradually decrease over the course of 3-4 weeks. After this time, nicotine should be completely eliminated from one's system, but psychological effects often continue to persist.

 

When nicotine enters the bloodstream, it activates the reward and pleasure pathways in the brain by increasing the levels of dopamine, a neurotransmitter responsible for feelings of well-being. It is known to affect areas in the brain that regulate breathing, memory (enhancing it), appetite, and heart rate. The brain quickly becomes addicted to this stimulating effect.

 

Additionally, smokers often turn to smoking when socializing with friends, feeling bored, or in need of a pick-me-up. Over time, this can cause the brain to associate smoking with pleasure, making it difficult to overcome psychological withdrawal symptoms even after overcoming physical nicotine withdrawal symptoms.

 

The physical symptoms of nicotine withdrawal.

 

When the nicotine receptors in the brain are suddenly deprived of nicotine, the release of dopamine decreases. This can naturally lead to an uncomfortable sensation and a strong craving for smoking, as the body has become accustomed to the need for dopamine release. The craving for nicotine can last for 5 to 30 minutes, can be very uncomfortable, and will only subside over time or with the use of nicotine replacement therapy (NRT).

 

A recent study titled "Quitting Smoking Increases Junk Food Intake: The Role of Endogenous Opioid System" has been published in the Journal of Drug and Alcohol Dependence. The lead author of the study, Dr. Mustafa al'Absi, is a licensed psychologist and professor in the Department of Family Medicine and Bio-behavioral Health at the University of Minnesota Medical School. His team researched the brain functions responsible for addiction and appetite regulation, specifically examining the potential preference for junk food during nicotine withdrawal.

 

Researchers studied a group of smoking and non-smoking participants between the ages of 18 and 75. They were randomly assigned to quit using nicotine products for 24 hours and given either a placebo or 50mg of naltrexone. At the end of each session, participants were given snacks with varying calorie levels, salt, sugar, and fat content.

 

As expected, a research group has found that participants who quit smoking tend to choose foods that are high in calories, salt, fat, and sugar. The study observed the involvement of receptors in the brain's opioid system in this behavior. The study shows that food choices and consumption are influenced by smoking status (abstinence > occasional smokers or non-smokers; p < .05), opioid antagonists (naltrexone < placebo; p < .05), and gender (males > females; p < .05). These effects were confirmed for high-sugar and high-fat foods, but no differences were found in low-sugar and low-fat foods.

 

Researchers have concluded that the use of food, particularly high-calorie food, is often employed as a coping mechanism for the negative effects and discomfort experienced by individuals during the process of quitting smoking.

 

(Source: Vaping Post)

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
UK Vape Maker Riot Enters Clacton By-Election to Fight Government 'White Packaging' Proposals
UK Vape Maker Riot Enters Clacton By-Election to Fight Government 'White Packaging' Proposals
British e-liquid manufacturer Riot Labs has introduced a fictional “candidate” called Riot Man around the Clacton parliamentary by-election, seeking to mobilize consumers and retailers against parts of the UK government’s proposed restrictions on vape packaging, device appearance and retail displays. Riot Man is not listed as an official candidate.
Aug.12
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
According to Law360 on August 31, 2026, a federal judge in North Carolina ruled that a patent sublicense between R.J. Reynolds Vapor Co. and Juul Labs Inc. relieves Reynolds of its obligation to continue paying royalties to Altria Client Services LLC over Vuse Alto. A jury had previously found that Vuse Alto infringed three Altria patents and awarded approximately $95.2 million in past damages, after which Reynolds was ordered to pay an ongoing royalty equal to 5.25% of positive net sales. The new ruling finds that a valid sublicense can eliminate future infringement, potentially ending what Altria described as hundreds of millions of dollars in future royalties.
Sep.01
Philippines Weighs Unified Vape Tax as Lawmakers Back Risk-Based Rates and Government Seeks to Fill ₱66 Billion Revenue Gap
Philippines Weighs Unified Vape Tax as Lawmakers Back Risk-Based Rates and Government Seeks to Fill ₱66 Billion Revenue Gap
Philippine lawmakers are considering an overhaul of the country's vape excise-tax regime to eliminate the wide gap between taxes on nicotine salt and freebase nicotine liquids and reduce incentives for misdeclaration. House Bill 5364, filed by Rep. Rufus Rodriguez and Rep. Maximo Rodriguez Jr., would impose a unified ₱10-per-milliliter tax on vapor products, with 5% annual increases beginning in 2027. Rodriguez says the proposal could generate an average ₱6 billion in annual collections from 2027 through 2030. The debate comes as the Philippine government considers tobacco, vape and other health-tax reforms to help offset around ₱66 billion in revenue expected to be forgone under a proposed tax-relief package.
Aug.18
JTI Makes Third Bet on South Korea as Ploom AURA Enters a Market Dominated by lil and IQOS
JTI Makes Third Bet on South Korea as Ploom AURA Enters a Market Dominated by lil and IQOS
Japan Tobacco International is stepping up its heated tobacco push in South Korea with Ploom AURA. Since its official launch in April 2026, the device's limited First Edition and Glacier White version have sold out, while distribution has expanded across Seoul, Incheon, Gyeonggi Province and airport duty-free channels. The rollout marks JTI's third major attempt to build a stronger heated tobacco position in South Korea, following Ploom TECH in 2019 and Ploom X Advanced in 2024. At the group level, JT plans to invest about ¥800 billion, approximately $5 billion, in reduced-risk products from 2026 through 2028, with heated products and Ploom identified as its primary investment priority.
Aug.14
From Nicotine Pouches to Soft Candy Forms: China Tobacco Hubei explores adjustable-release oral nicotine products
From Nicotine Pouches to Soft Candy Forms: China Tobacco Hubei explores adjustable-release oral nicotine products
China-based China Tobacco Hubei Industrial Co., Ltd. has filed a patent application covering an oral nicotine product and its preparation method. The patent proposes a soft candy-shaped oral nicotine product containing nicotine ingredients, gelling agents, sweeteners and alkaline pH regulators. Through formulation adjustments and homogeneous or dual-layer structures, the technology aims to achieve different nicotine release profiles. The filing reflects exploration of new oral nicotine product formats and controlled nicotine delivery approaches.
Aug.06